Global Preventable Vaccines

Preventable Vaccines Comprehensive Study by Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Others), Application (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella (MMR), Other Disease), End Use (Hospitals, Specialty Clinics, Vaccine Centers) Players and Region - Global Market Outlook to 2030

Preventable Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Preventable Vaccines Market Overview:
The increasing prevalence of infectious illnesses, innovative technology in vaccine research, higher financing from government and international organizations, and increased awareness of preventative care are all contributing to the worldwide preventive vaccines market's rise. The rising prevalence of the disease, as well as the availability of preventive vaccinations, are projected to drive market expansion.

Growth Drivers
  • Growing Prevalence of Infectious Diseases
  • Innovative Technology in Vaccine Development

Roadblocks
  • Risk of Adverse Effects

Opportunities
  • Rising Opportunities in Emerging Markets such as India, China, etc
  • Increasing Government Focus on Immunization Programs

Challenges
  • High Cost of Vaccine Development


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.
Some of the key players profiled in the report are AstraZeneca (United Kingdom), GlaxoSmithKline (United Kingdom), Merck (Germany), Takeda Pharmaceutical (Japan), Mitsubishi Tanabe Pharma (Japan), Sanofi (France), Pfizer (United States), Abbott (United States), Novartis (Switzerland) and Roche (Switzerland). Analyst at AMA Research see Global Players to retain maximum share of Global Preventable Vaccines market by 2026. Considering Market by End Use, the sub-segment i.e. Hospitals will boost the Preventable Vaccines market.

What Can be Explored with the Preventable Vaccines Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Preventable Vaccines Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Preventable Vaccines
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Preventable Vaccines market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Preventable Vaccines market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Preventable Vaccines Manufactures, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Live/Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Others
By Application
  • Pneumococcal
  • Poliovirus
  • Hepatitis
  • Influenza
  • Measles, Mumps, and Rubella (MMR)
  • Other Disease
By End Use
  • Hospitals
  • Specialty Clinics
  • Vaccine Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Infectious Diseases
      • 3.2.2. Innovative Technology in Vaccine Development
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Vaccine Development
    • 3.4. Market Trends
      • 3.4.1. Increased Funding from Government and International Organizations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Preventable Vaccines, by Type, Application, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Preventable Vaccines (Value)
      • 5.2.1. Global Preventable Vaccines by: Type (Value)
        • 5.2.1.1. Live/Attenuated Vaccines
        • 5.2.1.2. Inactivated Vaccines
        • 5.2.1.3. Subunit Vaccines
        • 5.2.1.4. Toxoid Vaccines
        • 5.2.1.5. Others
      • 5.2.2. Global Preventable Vaccines by: Application (Value)
        • 5.2.2.1. Pneumococcal
        • 5.2.2.2. Poliovirus
        • 5.2.2.3. Hepatitis
        • 5.2.2.4. Influenza
        • 5.2.2.5. Measles, Mumps, and Rubella (MMR)
        • 5.2.2.6. Other Disease
      • 5.2.3. Global Preventable Vaccines by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Vaccine Centers
      • 5.2.4. Global Preventable Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Preventable Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda Pharmaceutical (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mitsubishi Tanabe Pharma (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Roche (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Preventable Vaccines Sale, by Type, Application, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Preventable Vaccines (Value)
      • 7.2.1. Global Preventable Vaccines by: Type (Value)
        • 7.2.1.1. Live/Attenuated Vaccines
        • 7.2.1.2. Inactivated Vaccines
        • 7.2.1.3. Subunit Vaccines
        • 7.2.1.4. Toxoid Vaccines
        • 7.2.1.5. Others
      • 7.2.2. Global Preventable Vaccines by: Application (Value)
        • 7.2.2.1. Pneumococcal
        • 7.2.2.2. Poliovirus
        • 7.2.2.3. Hepatitis
        • 7.2.2.4. Influenza
        • 7.2.2.5. Measles, Mumps, and Rubella (MMR)
        • 7.2.2.6. Other Disease
      • 7.2.3. Global Preventable Vaccines by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Vaccine Centers
      • 7.2.4. Global Preventable Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Preventable Vaccines: by Type(USD Million)
  • Table 2. Preventable Vaccines Live/Attenuated Vaccines , by Region USD Million (2015-2020)
  • Table 3. Preventable Vaccines Inactivated Vaccines , by Region USD Million (2015-2020)
  • Table 4. Preventable Vaccines Subunit Vaccines , by Region USD Million (2015-2020)
  • Table 5. Preventable Vaccines Toxoid Vaccines , by Region USD Million (2015-2020)
  • Table 6. Preventable Vaccines Others , by Region USD Million (2015-2020)
  • Table 7. Preventable Vaccines: by Application(USD Million)
  • Table 8. Preventable Vaccines Pneumococcal , by Region USD Million (2015-2020)
  • Table 9. Preventable Vaccines Poliovirus , by Region USD Million (2015-2020)
  • Table 10. Preventable Vaccines Hepatitis , by Region USD Million (2015-2020)
  • Table 11. Preventable Vaccines Influenza , by Region USD Million (2015-2020)
  • Table 12. Preventable Vaccines Measles, Mumps, and Rubella (MMR) , by Region USD Million (2015-2020)
  • Table 13. Preventable Vaccines Other Disease , by Region USD Million (2015-2020)
  • Table 14. Preventable Vaccines: by End Use(USD Million)
  • Table 15. Preventable Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 16. Preventable Vaccines Specialty Clinics , by Region USD Million (2015-2020)
  • Table 17. Preventable Vaccines Vaccine Centers , by Region USD Million (2015-2020)
  • Table 18. South America Preventable Vaccines, by Country USD Million (2015-2020)
  • Table 19. South America Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 20. South America Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 21. South America Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 22. Brazil Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 23. Brazil Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 24. Brazil Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 25. Argentina Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 26. Argentina Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 27. Argentina Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 28. Rest of South America Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 31. Asia Pacific Preventable Vaccines, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 35. China Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 36. China Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 37. China Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 38. Japan Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 39. Japan Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 40. Japan Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 41. India Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 42. India Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 43. India Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 44. South Korea Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 45. South Korea Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 46. South Korea Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 47. Taiwan Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 48. Taiwan Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 49. Taiwan Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 50. Australia Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 51. Australia Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 52. Australia Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 56. Europe Preventable Vaccines, by Country USD Million (2015-2020)
  • Table 57. Europe Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 58. Europe Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 59. Europe Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 60. Germany Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 61. Germany Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 62. Germany Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 63. France Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 64. France Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 65. France Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 66. Italy Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 67. Italy Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 68. Italy Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 69. United Kingdom Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 70. United Kingdom Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 71. United Kingdom Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 72. Netherlands Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 73. Netherlands Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 74. Netherlands Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 75. Rest of Europe Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 76. Rest of Europe Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 77. Rest of Europe Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 78. MEA Preventable Vaccines, by Country USD Million (2015-2020)
  • Table 79. MEA Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 80. MEA Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 81. MEA Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 82. Middle East Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 83. Middle East Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 84. Middle East Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 85. Africa Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 86. Africa Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 87. Africa Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 88. North America Preventable Vaccines, by Country USD Million (2015-2020)
  • Table 89. North America Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 90. North America Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 91. North America Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 92. United States Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 93. United States Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 94. United States Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 95. Canada Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 96. Canada Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 97. Canada Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 98. Mexico Preventable Vaccines, by Type USD Million (2015-2020)
  • Table 99. Mexico Preventable Vaccines, by Application USD Million (2015-2020)
  • Table 100. Mexico Preventable Vaccines, by End Use USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Preventable Vaccines: by Type(USD Million)
  • Table 112. Preventable Vaccines Live/Attenuated Vaccines , by Region USD Million (2021-2026)
  • Table 113. Preventable Vaccines Inactivated Vaccines , by Region USD Million (2021-2026)
  • Table 114. Preventable Vaccines Subunit Vaccines , by Region USD Million (2021-2026)
  • Table 115. Preventable Vaccines Toxoid Vaccines , by Region USD Million (2021-2026)
  • Table 116. Preventable Vaccines Others , by Region USD Million (2021-2026)
  • Table 117. Preventable Vaccines: by Application(USD Million)
  • Table 118. Preventable Vaccines Pneumococcal , by Region USD Million (2021-2026)
  • Table 119. Preventable Vaccines Poliovirus , by Region USD Million (2021-2026)
  • Table 120. Preventable Vaccines Hepatitis , by Region USD Million (2021-2026)
  • Table 121. Preventable Vaccines Influenza , by Region USD Million (2021-2026)
  • Table 122. Preventable Vaccines Measles, Mumps, and Rubella (MMR) , by Region USD Million (2021-2026)
  • Table 123. Preventable Vaccines Other Disease , by Region USD Million (2021-2026)
  • Table 124. Preventable Vaccines: by End Use(USD Million)
  • Table 125. Preventable Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 126. Preventable Vaccines Specialty Clinics , by Region USD Million (2021-2026)
  • Table 127. Preventable Vaccines Vaccine Centers , by Region USD Million (2021-2026)
  • Table 128. South America Preventable Vaccines, by Country USD Million (2021-2026)
  • Table 129. South America Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 130. South America Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 131. South America Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 132. Brazil Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 133. Brazil Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 134. Brazil Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 135. Argentina Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 136. Argentina Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 137. Argentina Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 138. Rest of South America Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 139. Rest of South America Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 140. Rest of South America Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 141. Asia Pacific Preventable Vaccines, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 143. Asia Pacific Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 144. Asia Pacific Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 145. China Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 146. China Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 147. China Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 148. Japan Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 149. Japan Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 150. Japan Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 151. India Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 152. India Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 153. India Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 154. South Korea Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 155. South Korea Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 156. South Korea Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 157. Taiwan Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 158. Taiwan Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 159. Taiwan Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 160. Australia Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 161. Australia Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 162. Australia Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 166. Europe Preventable Vaccines, by Country USD Million (2021-2026)
  • Table 167. Europe Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 168. Europe Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 169. Europe Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 170. Germany Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 171. Germany Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 172. Germany Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 173. France Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 174. France Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 175. France Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 176. Italy Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 177. Italy Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 178. Italy Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 179. United Kingdom Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 180. United Kingdom Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 181. United Kingdom Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 182. Netherlands Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 183. Netherlands Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 184. Netherlands Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 185. Rest of Europe Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 186. Rest of Europe Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 187. Rest of Europe Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 188. MEA Preventable Vaccines, by Country USD Million (2021-2026)
  • Table 189. MEA Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 190. MEA Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 191. MEA Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 192. Middle East Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 193. Middle East Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 194. Middle East Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 195. Africa Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 196. Africa Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 197. Africa Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 198. North America Preventable Vaccines, by Country USD Million (2021-2026)
  • Table 199. North America Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 200. North America Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 201. North America Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 202. United States Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 203. United States Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 204. United States Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 205. Canada Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 206. Canada Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 207. Canada Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 208. Mexico Preventable Vaccines, by Type USD Million (2021-2026)
  • Table 209. Mexico Preventable Vaccines, by Application USD Million (2021-2026)
  • Table 210. Mexico Preventable Vaccines, by End Use USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Preventable Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Preventable Vaccines: by Application USD Million (2015-2020)
  • Figure 6. Global Preventable Vaccines: by End Use USD Million (2015-2020)
  • Figure 7. South America Preventable Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Preventable Vaccines Share (%), by Country
  • Figure 9. Europe Preventable Vaccines Share (%), by Country
  • Figure 10. MEA Preventable Vaccines Share (%), by Country
  • Figure 11. North America Preventable Vaccines Share (%), by Country
  • Figure 12. Global Preventable Vaccines share by Players 2020 (%)
  • Figure 13. Global Preventable Vaccines share by Players (Top 3) 2020(%)
  • Figure 14. Global Preventable Vaccines share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 20. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Merck (Germany) Revenue: by Geography 2020
  • Figure 22. Takeda Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Takeda Pharmaceutical (Japan) Revenue: by Geography 2020
  • Figure 24. Mitsubishi Tanabe Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Mitsubishi Tanabe Pharma (Japan) Revenue: by Geography 2020
  • Figure 26. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi (France) Revenue: by Geography 2020
  • Figure 28. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer (United States) Revenue: by Geography 2020
  • Figure 30. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbott (United States) Revenue: by Geography 2020
  • Figure 32. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 34. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 36. Global Preventable Vaccines: by Type USD Million (2021-2026)
  • Figure 37. Global Preventable Vaccines: by Application USD Million (2021-2026)
  • Figure 38. Global Preventable Vaccines: by End Use USD Million (2021-2026)
  • Figure 39. South America Preventable Vaccines Share (%), by Country
  • Figure 40. Asia Pacific Preventable Vaccines Share (%), by Country
  • Figure 41. Europe Preventable Vaccines Share (%), by Country
  • Figure 42. MEA Preventable Vaccines Share (%), by Country
  • Figure 43. North America Preventable Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • GlaxoSmithKline (United Kingdom)
  • Merck (Germany)
  • Takeda Pharmaceutical (Japan)
  • Mitsubishi Tanabe Pharma (Japan)
  • Sanofi (France)
  • Pfizer (United States)
  • Abbott (United States)
  • Novartis (Switzerland)
  • Roche (Switzerland)
Select User Access Type

Key Highlights of Report


Jan 2024 246 Pages 59 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Preventable Vaccines Quantitative research analysis
Global Preventable Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Preventable Vaccines market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Preventable Vaccines market are AstraZeneca (United Kingdom), GlaxoSmithKline (United Kingdom), Merck (Germany), Takeda Pharmaceutical (Japan), Mitsubishi Tanabe Pharma (Japan), Sanofi (France), Pfizer (United States), Abbott (United States), Novartis (Switzerland) and Roche (Switzerland), to name a few.
"Increased Funding from Government and International Organizations" is seen as one of major influencing trends for Preventable Vaccines Market during projected period 2020-2026.

Know More About Global Preventable Vaccines Report?

Have a Query? Click Here

Other Related Reports

Influenza Medication Comprehensive Study by Type (Zanamivir, Oseltamivir phosphate, Peramivir, Other Influenza Medication), Application (Hospitals, Clinics, Pharmacies, Others), Treatment Type (Medic...
$ 3450
Raynauds Disease Treatment Comprehensive Study by Type (Primary, Secondary), Application (Hospital, Clinic, Others), Treatment (Medication, - Calcium Channel Blockers, - Vasodilator, Surgeries and Me...
$ 3750
Plasma Therapy Comprehensive Study by Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), Application (Orthopedics (Arthritis, Chronic Tendinitis, Bon...
$ 3750
Poultry Bacteriology Diagnostics Comprehensive Study by Type (ELISA Test, PCR Test, Others), Application (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Mycoplasmosis, Avian Pasteurel...
$ 3750
Cold Pain Therapy Comprehensive Study by Type (OTC-Based Products, Prescription-Based Products), Application (Musculoskeletal Disorders, Sport Medicine, Physical Therapy, Post Operative Therapy, Post...
$ 3450
Synovial Sarcoma Treatment Comprehensive Study by Type (High-grade, Low-grade, Translocation-associated), End Users (Hospitals, Specialty Clinics, Oncology Centers, Other), Treatment (Surgery, Anti-A...
$ 3500